Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
26874-1-PBS targets SLC35A3 in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag25468 Product name: Recombinant human SLC35A3 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 158-220 aa of BC005136 Sequence: SDSQLDSKELSAGSQFVGLMAVLTACFSSGFAGVYFEKILKETKQSVWIRNIQLVSFSLEPSL 相同性解析による交差性が予測される生物種 |
| Full Name | solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 |
| Calculated molecular weight | 325 aa, 36 kDa |
| Observed molecular weight | 32-36 and 41 kDa |
| GenBank accession number | BC005136 |
| Gene Symbol | SLC35A3 |
| Gene ID (NCBI) | 23443 |
| RRID | AB_2880665 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9Y2D2 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
SLC35A3, also named as UDP-N-acetylglucosamine transporter(NGT), is located to the Golgi apparatus. SLC35A3 can form heterologous complexes with SLC35A2(UGT) and Mgats in the Golgi membrane which may promote biosynthesis of complex N-glycans. It has been reported that the mutation of SLC35A3 is associsted with skeletal dysplasia and epilepsies which could result from impaired glycosylation of proteins. SLC35A3 has some isoforms with 32-36 kDa and 41 kDa.(PMID: 25944901, 28777481 , 16344554, 23583405)